Bio Green Med Solution (UXI1) AI Stock Analysis

Bio Green Med Solution

(Munich:UXI1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRevenue growth indicates improving commercialization traction and expanding business activity versus prior years. If maintained, the larger revenue base could provide operating leverage and support investment in the company’s evolving business model over the next several quarters.

Negative Factors

Severe Operating LossesThe company has not yet demonstrated a scalable cost structure: operating losses exceed revenue and the net loss remains substantial. Continued losses can consume equity, limit internally funded growth, and make durable profitability dependent on a significant improvement in operating efficiency.

Bio Green Med Solution (UXI1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 4.97M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.2
Beta (1Y): -0.09
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 12
Sector: Industrials
Sector Strength: 63
Industry: Medical - Pharmaceuticals

Bio Green Med Solution Business Overview & Revenue Model

Company Description

Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitter...

Bio Green Med Solution Earnings Call Summary

Earnings Call Date:Aug 13, 2024(Q2-2024)|% Change Since:-99.48%|Next Earnings Date:May 06, 2025

Earnings Call SentimentPositive

The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.

Positive Updates

Progress in Fadra Phase II Study

Cyclacel reported successful recruitment in the enriched cohort of their Phase II proof-of-concept study for fadra, with positive preliminary signals in heavily pretreated patients across various cancer types. Initial clinical activity is expected to be reported in Q4 2024.

Negative Updates

Decrease in R&D Tax Credits

UK research and development tax credits decreased significantly to $0.4 million for Q2 2024, compared to $6 million for the same period in the previous year.

Company Guidance

During the Cyclacel Q2 2024 earnings call, the company provided key updates on their precision medicine strategy, particularly focusing on fadra, an oral CDK2/9 inhibitor. Recruitment is progressing well in the 065-101 Phase II proof-of-concept study, with an enriched cohort targeting patients with CDKN2A and CDK NIB chromosomal abnormalities. Initial clinical activity results are expected in Q4 2024. Financially, Cyclacel reported cash equivalents of $6 million as of June 2024, with net cash used in operating activities amounting to $3.6 million for the first half of the year, indicating a decrease from $8.2 million in the same period of 2023. Research and development expenses for the quarter were $2 million, a reduction from $4.7 million in Q2 2023, with specific R&D expenses for fadra at $1.5 million, down from $3 million the previous year. The company anticipates that current cash resources will cover planned programs into the fourth quarter of 2024.

Bio Green Med Solution Risk Analysis

Bio Green Med Solution disclosed 63 risk factors in its most recent earnings report. Bio Green Med Solution reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Bio Green Med Solution Peers Comparison

Overall Rating

UnderperformOutperform

Sector (63)

Financial Indicators

DE:UXI1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
BDRX	48Neutral	$1.80M	-52.22	-42.42%	―	―	97.97%
NEUP	48Neutral	$16.50M	-0.42	-77.03%	―	―	―
BJDX	44Neutral	$2.49M	-0.04	-125.01%	―	―	93.91%
RNTX	32Underperform	$57.80M	-0.35	-234.45%	―	―	36.23%

* Industrials Sector Average

Performance Comparison

DE:UXI1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:UXI1	Bio Green Med Solution, Inc.	1.48	-0.07	-4.53%
BDRX	Biodexa Pharmaceuticals Plc	2.80	-213.20	-98.70%
RNTX	Rein Therapeutics, Inc	0.64	-0.78	-55.28%
BJDX	Bluejay Diagnostics, Inc.	0.53	-6.63	-92.60%
NEUP	Neuphoria Therapeutics Inc.	3.04	-1.18	-27.96%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Bio Green Med Solution AI Stock Analysis